Scarica l'app Stockscreener
1.0309
0.99%
-0.0191
Precedente Chiudi:
$1.05
Aprire:
$1.06
Volume 24 ore:
163.34K
Relative Volume:
0.22
Capitalizzazione di mercato:
$78.88M
Reddito:
$8.23M
Utile/perdita netta:
$-32.49M
Rapporto P/E:
-1.7473
EPS:
-0.59
Flusso di cassa netto:
$-19.91M
1 W Prestazione:
-0.99%
1M Prestazione:
-21.24%
6M Prestazione:
-30.23%
1 anno Prestazione:
+9.43%
Intervallo 1D:
$1.03
$1.08
Intervallo di 1 settimana:
$0.9757
$1.08
Portata 52W:
$0.92
$2.12
Clearside Biomedical Inc Stock (CLSD) Company Profile
Nome
Clearside Biomedical Inc
Settore
Industria
Telefono
678-270-3631
Indirizzo
900 NORTH POINT PARKWAY, ALPHARETTA, GA
Confronta CLSD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| CLSD | 1.0309 | 78.88M | 8.23M | -32.49M | -19.91M | -0.59 |
| VRTX | 450.26 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.54 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.88 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.32 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.58 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-12-15 | Ripresa | Wedbush | Outperform |
| 2021-07-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-13 | Iniziato | ROTH Capital | Buy |
| 2019-08-09 | Downgrade | Needham | Buy → Hold |
| 2018-11-05 | Downgrade | Cowen | Outperform → Market Perform |
| 2018-11-05 | Downgrade | JP Morgan | Overweight → Underweight |
| 2018-11-05 | Downgrade | Stifel | Buy → Hold |
| 2018-03-06 | Reiterato | Needham | Buy |
| 2017-05-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2017-02-24 | Iniziato | JP Morgan | Overweight |
| 2016-11-10 | Reiterato | Needham | Buy |
| 2016-10-24 | Reiterato | Stifel | Buy |
Mostra tutto
Clearside Biomedical Inc Borsa (CLSD) Ultime notizie
Clearside Biomedical’s (CLSD) Buy Rating Reaffirmed at HC Wainwright - Defense World
What is HC Wainwright's Forecast for CLSD FY2024 Earnings? - MarketBeat
Clearside Biomedical, Inc. (NASDAQ:CLSD) Sees Significant Decline in Short Interest - MarketBeat
Clearside Biomedical's (CLSD) Buy Rating Reaffirmed at Chardan Capital - MarketBeat
Clearside Biomedical (NASDAQ:CLSD) Raised to Hold at StockNews.com - MarketBeat
All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy - MSN
Clearside Biomedical Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Needham & Company LLC Reaffirms Buy Rating for Clearside Biomedical (NASDAQ:CLSD) - Defense World
Clearside Biomedical (NASDAQ:CLSD) Given Buy Rating at HC Wainwright - MarketBeat
Clearside Biomedical Announces Slight Revenue Increase in Third Quarter, Advances Wet AMD Treatment in Clinical Trial - Vision Monday
Earnings call: Clearside Biomedical reports progress in AMD treatment - Investing.com
Earnings call: Clearside Biomedical reports progress in AMD treatment By Investing.com - Investing.com Australia
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue Estimates - MSN
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2024 Earnings Call Transcript - Insider Monkey
Clearside Biomedical's (CLSD) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Call Highlights - GuruFocus.com
Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Call Highlights: Promising Clinical Trial ... - Yahoo Finance
Clearside Biomedical Reports Positive Q3 2024 Results - TipRanks
Clearside Biomedical Inc (CLSD) Q3 2024 Earnings: Revenue Surges - GuruFocus.com
Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Clearside Biomedical earnings beat by $0.02, revenue topped estimates - Investing.com UK
Clearside Biomedical Hits Phase 2b Trial Success, Advances AMD Treatment to Phase 3 | CLSD Stock News - StockTitan
Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Call Highlights: Promising Clinical Trial ... By GuruFocus - Investing.com Canada
Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Report Preview: What to Look For - GuruFocus.com
Even after rising 13% this past week, Clearside Biomedical (NASDAQ:CLSD) shareholders are still down 77% over the past three years - Yahoo Finance
Clearside Biomedical (NASDAQ:CLSD) Rating Lowered to "Sell" at StockNews.com - MarketBeat
Clearside inks deal to expand eye treatment in China - Investing.com
Clearside inks deal to expand eye treatment in China By Investing.com - Investing.com UK
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema - GlobeNewswire
Clearside's Eye Treatment Platform Gains Momentum with Major Santen Partnership in China | CLSD Stock News - StockTitan
Rosalind Advisors Inc. Lowers Stock Holdings in Clearside Biomedical, Inc. (NASDAQ:CLSD) - MarketBeat
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference - GlobeNewswire
Clearside Biomedical CEO to Present at Stifel Healthcare ConferenceKey Updates Expected | CLSD Stock News - StockTitan
Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors - Vision Monday
Clearside Biomedical (CLSD) Scheduled to Post Earnings on Tuesday - MarketBeat
Clearside Biomedical names new board chair By Investing.com - Investing.com Canada
Clearside Biomedical, Inc. (NASDAQ:CLSD) Insider Purchases $36,500.00 in Stock - MarketBeat
Clearside Biomedical chief medical officer buys $36,500 in stock - Investing.com
Clearside Biomedical chief medical officer buys $36,500 in stock By Investing.com - Investing.com Australia
Clearside Biomedical names new board chair - Investing.com
Clearside Biomedical to Report Third Quarter 2024 Financial - GlobeNewswire
Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024 - The Manila Times
Clearside’s CLS-AX shows promise in treatment of wet age-related macular degeneration - 2 Minute Medicine
Brokerages Set Clearside Biomedical, Inc. (NASDAQ:CLSD) Price Target at $5.17 - MarketBeat
Short Interest in Clearside Biomedical, Inc. (NASDAQ:CLSD) Rises By 646.6% - MarketBeat
Clearside Biomedical advances CLS-AX into Phase 3 trials By Investing.com - Investing.com Nigeria
Clearside Biomedical Inc Still Hasn’t Convinced Analysts? - Stocks Register
Clearside Biomedical advances CLS-AX into Phase 3 trials - Investing.com
Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting - ForexTV.com
Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and - GlobeNewswire
Clearside Biomedical (NASDAQ:CLSD) Stock Rating Upgraded by StockNews.com - Defense World
Clearside Biomedical Inc Azioni (CLSD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):